This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.
Joud Hajjar, B. Stephen, A. Aaroe et al.· Journal of Immunotherapy and...· 1 citation
The findings of this cohort study suggest that the high prevalence of TERT promoter variants in older patients largely explains the association between age and worse prognosis in PTC.
V. R. Marczyk, Sophie Li, Chia C. Wu et al.· JAMA Otolaryngology - Head a...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.